- Home
- NBRG vs ELTX Comparison
NBRG vs ELTX Comparison
Compare NBRG & ELTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NBRG | ELTX |
|---|---|---|
| Founded | 2021 | 2011 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 75.3M | 81.2M |
| IPO Year | 2025 | 2014 |
Fundamental Metrics
Financial Performance| Metric | NBRG | ELTX |
|---|---|---|
| Price | $10.04 | $3.00 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $18.00 |
| AVG Volume (30 Days) | 97.0K | ★ 265.1K |
| Earning Date | N/A | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 39.29 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,301,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.59 | $2.66 |
| 52 Week High | $10.05 | $16.00 |
Technical Indicators
Market Signals| Indicator | NBRG | ELTX |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 39.54 |
| Support Level | N/A | $2.72 |
| Resistance Level | N/A | $3.32 |
| Average True Range (ATR) | 0.00 | 0.14 |
| MACD | 0.00 | 0.08 |
| Stochastic Oscillator | 0.00 | 9.52 |
Price Performance
Historical ComparisonAbout NBRG Newbridge Acquisition Limited Class A Ordinary Share
Newbridge Acquisition Ltd is a blank check company.
About ELTX Elicio Therapeutics Inc.
Elicio Therapeutics Inc is a clinical-stage biotechnology company advancing novel immunotherapies for the treatment of cancer, including mKRAS-positive pancreatic cancer, colorectal cancer (CRC), lung cancer, and other mKRAS-positive cancers. The Company focuses on developing effective, off-the-shelf immunotherapies using its proprietary Amphiphile (AMP) technology, which aims to enhance the education, activation, and amplification of cancer-specific T cells to promote durable cancer immunosurveillance. Its clinical pipeline includes ELI-002 7P, a lymph node-targeted cancer immunotherapy currently being evaluated in a Phase 2 study for mKRAS pancreatic ductal adenocarcinoma (PDAC), a common form of pancreatic cancer.